What medications are recommended after cardiac arrest in a patient with Brugada syndrome?

Post-Cardiac Arrest Management in Brugada Syndrome

An ICD is the primary recommended therapy for Brugada syndrome patients who survive cardiac arrest, with quinidine as the key adjunctive medication for preventing recurrent arrhythmias 1.

Primary Recommendation: ICD Implantation

The 2017 AHA/ACC/HRS guidelines provide a Class I, Level B-NR recommendation that patients with Brugada syndrome who have experienced cardiac arrest should receive an ICD if meaningful survival greater than 1 year is expected 1. This is the cornerstone of therapy and takes precedence over all other interventions.

Pharmacological Management

For Recurrent ICD Shocks or Electrical Storm

Quinidine is the first-line medication for patients experiencing recurrent ICD shocks or electrical storm 1. The guidelines give this a Class I recommendation, making it the strongest evidence-based pharmacological option.

• Mechanism: Quinidine blocks the Ito current, rebalancing the action potential and preventing the substrate for ventricular arrhythmias 2, 3
• Efficacy: Long-term data shows 90% electrophysiological response rates with no arrhythmic events during therapy in responders over a mean follow-up of 113 months 4
• Dosing consideration: Should be guided by electrophysiological testing when possible 4

Acute Management of Electrical Storm

When immediate control is needed:

• Isoproterenol (with or without quinidine) is effective in 35.5% of electrical storm cases 5
• Beta-adrenergic stimulation produces an inward shift in ion currents, counteracting the arrhythmogenic substrate 3
• Important caveat: One recent case report suggests low-dose adrenaline may be an alternative when isoproterenol is unavailable 6, though this is based on limited evidence

Avoid these medications - they are ineffective or contraindicated:

• Lidocaine (failed to control electrical storm) 5
• Magnesium sulfate 5
• Mexiletine 5
• Propranolol 5

Alternative Pharmacological Options

If quinidine is not tolerated or unavailable:

• Disopyramide: Another Class 1A agent with similar efficacy (~90% response rate) 4
• Cilostazol: Phosphodiesterase III inhibitor that augments calcium current 7, 6
• Combination therapy: Quinidine plus cilostazol for long-term suppression 6

Catheter Ablation

The guidelines recommend catheter ablation as an alternative to quinidine (Class I recommendation) for patients with recurrent ICD shocks 1. This targets the right ventricular outflow tract epicardium where the arrhythmogenic substrate originates 3.

Critical Pitfalls to Avoid

1. Do not use sodium channel blockers therapeutically - while they unmask the ECG pattern diagnostically 1, 8, they worsen the underlying pathophysiology
2. Do not delay ICD implantation in cardiac arrest survivors - this is non-negotiable per guidelines 1
3. Do not use amiodarone or standard ACLS antiarrhythmics - these are ineffective in Brugada syndrome 5
4. Avoid fever - aggressively treat with antipyretics as fever can trigger arrhythmias

Long-Term Management Algorithm

1. ICD implantation (mandatory for cardiac arrest survivors)
2. Add quinidine if recurrent shocks occur or for additional protection
3. Consider catheter ablation if quinidine fails or is not tolerated
4. Genetic testing and counseling may be useful for family screening 1

The evidence strongly supports this hierarchical approach, with the 2017 guidelines providing the framework 1 and long-term outcome data confirming quinidine's safety and efficacy 4.